Valneva SE Sponsored ADR
VALN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 17.3%, EPS fell 222.1%, free cash flow fell 56.1% and total debt rose 12.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow VALN
Valneva SE Sponsored ADR (VALN) EV/Sales
As of 16 October 2026, Valneva SE Sponsored ADR (VALN) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from 1.3× (April 2023) to 25.3× (November 2021); the current reading is higher than 49% of that period. That is below the Biotechnology industry median of 9.2× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.1× | 97.77% |
| FY2024 | 2.1× | (26.63%) |
| FY2023 | 2.8× | 31.60% |
| FY2022 | 2.2× | (89.52%) |
| FY2021 | 20.6× | 143.85% |
| FY2020 | 8.4× | 0.00% |
| FY2019 | 8.4× | 0.00% |
| FY2018 | 8.4× | 0.00% |
| FY2017 | 8.4× | 0.00% |
| FY2016 | 8.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 3.9× | 23.98% |
| Mar 2025 | 3.2× | (8.91%) |
| Mar 2024 | 3.5× | 10.56% |
| Sep 2023 | 3.2× | 14.83% |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VECT VectivBio Holding AG compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| CRMD CorMedix Inc compare | 1.0× |
| PBYI Puma Biotechnology, Inc. compare | 1.9× |
| VALN Valneva SE Sponsored ADR | 3.5× |
| STTK Shattuck Labs, Inc. compare | 88.3× |
| DBVT DBV Technologies S.A. compare | 124× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 403× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)